From: Cellular immunotherapy for refractory hematological malignancies
Malignancy
Complete response
Partial response
Transient response
Total response
AML
3/13 (23%)
0/13 (0%)
7/13 (54%)
10/13 (77%)
NHL
2/6 (33%)
0/6 (0%)
4/6 (66%)